JP4698235B2 - ヒトにおける炎症性腸疾患の処置用の薬学的組成物を製造するためのアセキサム酸亜鉛の使用 - Google Patents
ヒトにおける炎症性腸疾患の処置用の薬学的組成物を製造するためのアセキサム酸亜鉛の使用 Download PDFInfo
- Publication number
- JP4698235B2 JP4698235B2 JP2005018225A JP2005018225A JP4698235B2 JP 4698235 B2 JP4698235 B2 JP 4698235B2 JP 2005018225 A JP2005018225 A JP 2005018225A JP 2005018225 A JP2005018225 A JP 2005018225A JP 4698235 B2 JP4698235 B2 JP 4698235B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- zinc
- inflammatory bowel
- bowel disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims description 35
- 239000011701 zinc Substances 0.000 title claims description 35
- 229910052725 zinc Inorganic materials 0.000 title claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 27
- 238000011282 treatment Methods 0.000 title claims description 25
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 description 16
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 11
- 208000025865 Ulcer Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- WDSCBUNMANHPFH-UHFFFAOYSA-N acexamic acid Chemical compound CC(=O)NCCCCCC(O)=O WDSCBUNMANHPFH-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 241000792859 Enema Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000007920 enema Substances 0.000 description 4
- 229940095399 enema Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229960004582 acexamic acid Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960003476 methylparaben sodium Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 2
- 230000002178 gastroprotective effect Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- OWSBHFWSKFIEGF-UHFFFAOYSA-M sodium;methyl carbonate Chemical compound [Na+].COC([O-])=O OWSBHFWSKFIEGF-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000008638 inflammatory bowel disease 1 Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明の1つの主題は、アセキサム酸亜鉛が主な有効成分である調製物(preparations)による炎症性腸疾患の処置方法を提供することである。
1. ヒトにおける炎症性腸疾患の処置用の薬学的組成物を製造するためのアセキサム酸亜鉛の使用。
2. 前記薬学的組成物がヒトにおける潰瘍性大腸炎の処置用であることを特徴とする、項1に記載の使用。
3. 前記薬学的組成物がヒトにおけるクローン病の処置用であることを特徴とする、項1に記載の使用。
4. 前記薬学的組成物が有効成分としてアセキサム酸亜鉛のみを含有することを特徴とする、項1〜3のいずれか1項に記載の使用。
5. 前記薬学的組成物が経口投与用であることを特徴とする、項1〜4のいずれか1項に記載の使用。
6. 前記薬学的組成物が直腸投与用であることを特徴とする、項1〜4のいずれか1項に記載の使用。
7. 前記薬学的組成物が、20〜500mgのアセキサム酸亜鉛を含む単位投薬形態で投与されることを特徴とする、項1〜6のいずれか1項に記載の使用。
炎症性腸プロセス(inflamed bowel process)に対するアセキサム酸亜鉛の効果を研究した。
1. 未処置のコントロール。
2. 100mg/kgの経口用量レベルでアセキサム酸亜鉛で毎日処置した。
3. 1週間に3日、0.5ml浣腸として投与した局所アセキサム酸亜鉛(20mg/ml)で処置した。
0:病巣無し。
1:うっ血。潰瘍無し。
2:うっ血および腸管壁の肥厚、潰瘍無し。
3:潰瘍1つ。腸管壁の肥厚無し。
4:潰瘍または炎症の病巣2つ以上。
5:潰瘍および炎症のより大きな病巣2つ以上、あるいは結腸に沿って1cm以上に広がっている潰瘍および炎症の病巣1つ。
6−10:病巣が2cm長以上である場合、スコアは、病巣の追加の1cmについて1単位増加する。
潰瘍:
潰瘍無し、上皮形成: 0
小さな潰瘍<3mm: 1
大きな潰瘍>3mm: 2
炎症:
無し: 0
僅か: 1
中程度: 2
重度: 3
病巣の深さ:
無し: 0
粘膜下組織: 1
筋肉(Muscular): 2
漿液(Serous): 3
線維形成(Fibrosis):
無し:0
僅か:1
重度:2
計算
肉眼的程度(Macroscopic degree):アドヒアランス(adherences)(1〜3)に寄与する値および病巣の値を加えることによって得た。
顕微鏡的程度(Microscopic degree):各アイテムについて得られたスコアを加えることによって得た。
実施例
a)処置の2週間後の肉眼的インデックス(Macroscopic index)
po:経口投与
ic:結腸内投与
sem:平均の標準誤差(standard error of the mean)。
調製物番号1
アセキサム酸亜鉛 300 mg
コーンスターチ 130 mg
ポリエチレングリコール 21 mg
タルク 15 mg
ポリビニルピロリドン 10 mg
スターチのカルボキシメチルエーテルのナトリウム塩 8 mg
ポリソルベート80 0.5 mg
1つの485 mg カプセル剤について。
アセキサム酸亜鉛 150 mg
コーンスターチ 65 mg
ポリエチレングリコール 10.5 mg
タルク 7.5 mg
ポリビニルピロリドン 5 mg
スターチのカルボキシメチルエーテルのナトリウム塩 4 mg
ポリソルベート80 0.25 mg
1つの243 mg カプセル剤について。
アセキサム酸亜鉛 27.8 g
液体ワセリン 135 g
自己乳化性グリセリンモノステアレート 67.5 g
液体ソルビトール70% 63 g
サッカロース 41 g
軽質酸化マグネシウム 9 g
安息香酸ナトリウム 1.8 g
サッカリンナトリウム 1.4 g
ポリソルベート60 0.4 g
メチルパラベンナトリウム 6.3 mg
プロピルパラベン 6.3 mg
精製水 900 gまで。
アセキサム酸亜鉛 0.300 g
ポリエチレングリコール 1.500 g
カルボキシメチルセルロースナトリウム 0.080 g
メチルパラベンナトリウム 0.030 g
乳酸 pH: 7-7.5まで
精製水 10 mlまで。
アセキサム酸亜鉛 0.200 g
ポリエチレングリコール 1.500 g
カルボキシメチルセルロースナトリウム 0.080 g
メチルパラベンナトリウム 0.030 g
乳酸 pH: 7-7.5まで
精製水 10 mlまで。
Claims (7)
- ヒトにおける炎症性腸疾患の処置用の薬学的組成物を製造するためのアセキサム酸亜鉛の使用。
- 前記薬学的組成物がヒトにおける潰瘍性大腸炎の処置用であることを特徴とする、請求項1に記載の使用。
- 前記薬学的組成物がヒトにおけるクローン病の処置用であることを特徴とする、請求項1に記載の使用。
- 前記薬学的組成物が有効成分としてアセキサム酸亜鉛のみを含有することを特徴とする、請求項1〜3のいずれか1項に記載の使用。
- 前記薬学的組成物が経口投与用であることを特徴とする、請求項1〜4のいずれか1項に記載の使用。
- 前記薬学的組成物が直腸投与用であることを特徴とする、請求項1〜4のいずれか1項に記載の使用。
- 前記薬学的組成物が、20〜500mgのアセキサム酸亜鉛を含む単位投薬形態で投与されることを特徴とする、請求項1〜6のいずれか1項に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200400247 | 2004-02-05 | ||
ES200400247A ES2238177B1 (es) | 2004-02-05 | 2004-02-05 | Uso de acexamato de zinc para la preparacion de una composicion farmaceutica para el tratamiento en humanos de la enfermedad inflamatoria intestinal. |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005220131A JP2005220131A (ja) | 2005-08-18 |
JP4698235B2 true JP4698235B2 (ja) | 2011-06-08 |
Family
ID=34854877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005018225A Active JP4698235B2 (ja) | 2004-02-05 | 2005-01-26 | ヒトにおける炎症性腸疾患の処置用の薬学的組成物を製造するためのアセキサム酸亜鉛の使用 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4698235B2 (ja) |
KR (1) | KR101142803B1 (ja) |
ES (1) | ES2238177B1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2438931A (en) * | 2006-06-07 | 2007-12-12 | Ahmed Mahmoud Hassan El-Tawil | Zinc is the magic solution for managing cases of inflammatory bowel diseases |
KR20100034721A (ko) * | 2008-09-24 | 2010-04-01 | 건일제약 주식회사 | Nsaid에 의해 유도된 장 병변을 예방 또는 치료하기 위한 아세삼산 아연을 포함하는 약학적 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3869615D1 (de) * | 1988-11-14 | 1992-04-30 | Vinas Lab | Verwendung von zinkacexamate zur prophylaxe der durch nsaid-induzierten gastropathie. |
JP2900056B2 (ja) * | 1990-04-10 | 1999-06-02 | ラボラトリオス ヴィニャス,エス.アー. | 非ステロイド抗炎症剤により生じる胃疾患の予防用医薬組成物 |
-
2004
- 2004-02-05 ES ES200400247A patent/ES2238177B1/es not_active Expired - Fee Related
-
2005
- 2005-01-26 JP JP2005018225A patent/JP4698235B2/ja active Active
- 2005-01-28 KR KR1020050008083A patent/KR101142803B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101142803B1 (ko) | 2012-05-09 |
JP2005220131A (ja) | 2005-08-18 |
ES2238177B1 (es) | 2006-04-01 |
ES2238177A1 (es) | 2005-08-16 |
KR20060042885A (ko) | 2006-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI536997B (zh) | 穿心蓮萃取物 | |
US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
CN108348636B (zh) | 贻贝粘蛋白产品及其抑制粘膜炎症的应用 | |
Mahattanadul et al. | Comparative antiulcer effect of bisdemethoxycurcumin and curcumin in a gastric ulcer model system | |
JP4698235B2 (ja) | ヒトにおける炎症性腸疾患の処置用の薬学的組成物を製造するためのアセキサム酸亜鉛の使用 | |
US20150265651A1 (en) | Herbal Composition for the Prevention and Treatment of TNF-ALPHA Mediated Diseases | |
JP7020915B2 (ja) | 抗炎症性、増殖性、保護性及び粘膜付着性の、可溶性且つ安定な医薬組成物、粘膜部位の状態を治療するためのその使用及び取得方法、並びに医薬組成物の調製のための基本医薬組成物及びその取得方法 | |
KR101145751B1 (ko) | 염증성 장 질환의 치료 또는 예방용 조성물 | |
JP2006515361A (ja) | ヘルペスウイルス感染の症候を治療又は予防する方法 | |
JP2007223971A (ja) | プロスタグランジンe2産生促進剤 | |
CN114712375A (zh) | 一种羟基白桦酸化合物在制备皮肤病药物中的应用 | |
JP2010083871A (ja) | 抗アデノウイルス剤を含有する医薬組成物 | |
KR20180124192A (ko) | 곡기생 추출물을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 조성물 | |
JP3002700B2 (ja) | 抗エイズウイルス剤 | |
CN114469955A (zh) | 喹唑啉衍生物在制备预防和/或治疗胃肠道疾病药物中的应用 | |
JP2009298702A (ja) | 経口用組成物 | |
KR100793236B1 (ko) | 대장염 치료용 약학적 조성물 | |
JP6149682B2 (ja) | 胃潰瘍予防剤 | |
RU2744455C1 (ru) | Способ профилактики язвообразования на слизистой оболочке желудка | |
WO2017117774A1 (zh) | 亚丁基苯酞的应用 | |
CN106798916A (zh) | 一种治疗hpv感染的组合物及其应用 | |
CN117427056A (zh) | 4,5,2'-三羟基-2,5'-二溴二苯甲酮在治疗炎症性肠病药物中的应用 | |
WO2007093090A1 (fr) | Application d'acide glycyrrhizique et son produit de décomposition pour la préparation d'un médicament pour le traitement de l'affection abdominale inflammatoire | |
JP2900056B2 (ja) | 非ステロイド抗炎症剤により生じる胃疾患の予防用医薬組成物 | |
CN115381820A (zh) | 盐酸去亚甲基四氢小檗碱在制备治疗溃疡性结肠炎药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071031 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110301 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4698235 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |